Van ECK Associates Corp lowered its position in shares of FMC Co. (NYSE:FMC – Free Report) by 2.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 542,917 shares of the basic materials company’s stock after selling 12,178 shares during the quarter. Van ECK Associates Corp owned 0.43% of FMC worth $33,721,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. Pallas Capital Advisors LLC boosted its stake in shares of FMC by 26.7% during the 3rd quarter. Pallas Capital Advisors LLC now owns 10,102 shares of the basic materials company’s stock worth $621,000 after acquiring an additional 2,129 shares during the period. Hunter Associates Investment Management LLC bought a new stake in FMC in the third quarter worth approximately $201,000. Nisa Investment Advisors LLC boosted its holdings in FMC by 3.9% in the third quarter. Nisa Investment Advisors LLC now owns 72,352 shares of the basic materials company’s stock worth $4,813,000 after acquiring an additional 2,692 shares in the last quarter. Tributary Capital Management LLC raised its position in FMC by 114.3% in the 3rd quarter. Tributary Capital Management LLC now owns 4,875 shares of the basic materials company’s stock valued at $321,000 after buying an additional 2,600 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of FMC by 7.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 14,515 shares of the basic materials company’s stock valued at $957,000 after purchasing an additional 980 shares during the last quarter. Institutional investors own 91.86% of the company’s stock.
FMC Stock Performance
Shares of FMC opened at $63.45 on Tuesday. FMC Co. has a 1 year low of $49.49 and a 1 year high of $68.72. The company has a market capitalization of $7.92 billion, a price-to-earnings ratio of 5.46, a PEG ratio of 1.66 and a beta of 0.85. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.07 and a current ratio of 1.48. The company’s 50 day simple moving average is $63.21 and its 200 day simple moving average is $60.96.
Analyst Ratings Changes
A number of research analysts have weighed in on FMC shares. BMO Capital Markets lifted their target price on FMC from $60.00 to $65.00 and gave the company a “market perform” rating in a report on Friday, August 2nd. Wells Fargo & Company reduced their price target on shares of FMC from $68.00 to $62.00 and set an “equal weight” rating for the company in a research report on Tuesday, July 16th. JPMorgan Chase & Co. increased their price target on FMC from $50.00 to $59.00 and gave the company a “neutral” rating in a report on Monday, August 12th. Barclays lifted their price target on FMC from $62.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Monday, August 5th. Finally, Citigroup started coverage on FMC in a research report on Wednesday, October 23rd. They set a “neutral” rating and a $67.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $68.00.
Check Out Our Latest Report on FMC
About FMC
FMC Corporation, an agricultural sciences company, provides crop protection, plant health, and professional pest and turf management products. It develops, markets, and sells crop protection chemicals that includes insecticides, herbicides, and fungicides; and biologicals, crop nutrition, and seed treatment products, which are used in agriculture to enhance crop yield and quality by controlling a range of insects, weeds, and diseases, as well as in non-agricultural markets for pest control.
See Also
- Five stocks we like better than FMC
- What is the Dogs of the Dow Strategy? Overview and Examples
- Intel: Is Now the Time to Be Brave?Â
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- How to Capture the Benefits of Dividend Increases
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for FMC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FMC and related companies with MarketBeat.com's FREE daily email newsletter.